Cargando…

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival

Objective. To define survival patterns of women with ovarian carcinosarcoma based on patient, tumor, and treatment characteristics. Methods/Materials. A single-institution, retrospective analysis of women diagnosed with ovarian carcinosarcoma from February 1993 to May 2009 was performed. Survival wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jernigan, Amelia M., Fader, Amanda Nickles, Nutter, Benjamin, Rose, Peter, Tseng, Jill H., Escobar, Pedro F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678456/ https://www.ncbi.nlm.nih.gov/pubmed/23781249 http://dx.doi.org/10.1155/2013/490508

Ejemplares similares

Laparoendoscopic Single-Site Surgery for Management of Ovarian Endometriomas
por: Bedaiwy, Mohamed A., et al.
Publicado: (2014)

Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer
por: Raj, Hemanth, et al.
Publicado: (2021)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Sweet's syndrome: a cutaneous harbinger of ovarian carcinoma
por: Fader, Amanda Nickles, et al.
Publicado: (2012)

Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management
por: Beavis, Anna L, et al.
Publicado: (2016)

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
por: Zou, Ruoyao, et al.
Publicado: (2023)

Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience
por: Nizam, Aaron, et al.
Publicado: (2019)

Ovarian Carcinosarcoma and Response to Immunotherapy
por: Daniyal, Muhammad, et al.
Publicado: (2023)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Establishment and validation of a novel nomogram for survival prediction of ovarian carcinosarcoma
por: Liu, Yi, et al.
Publicado: (2022)

Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control
por: Petrillo, Marco, et al.
Publicado: (2016)

Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Shin, Wonkyo, et al.
Publicado: (2020)

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
por: Jeong, Soo Young, et al.
Publicado: (2019)

Long term survival of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in advanced epithelial ovarian cancer
por: Zhang, Jue, et al.
Publicado: (2021)

Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
por: van de Laar, Rafli, et al.
Publicado: (2014)

Single-Port Laparoscopy, NOTES, and Endoluminal Surgery
por: Escobar, Pedro F., et al.
Publicado: (2010)

Laparoendoscopic single-site surgery in gynaecology: A new frontier in minimally invasive surgery
por: Fader, Amanda Nickles, et al.
Publicado: (2011)

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
por: Coleman, Robert L.
Publicado: (2020)

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer
por: Ferrandina, G, et al.
Publicado: (1999)

Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status
por: Penn, Courtney A., et al.
Publicado: (2022)

Impact of insurance status on overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
por: Chokshi, Ravi J., et al.
Publicado: (2020)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study
por: Kim, Se Ik, et al.
Publicado: (2023)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
por: Piso, Pompiliu, et al.
Publicado: (2004)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft
por: Glaser, Gretchen, et al.
Publicado: (2015)

Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
por: Sertier, Anne-Sophie, et al.
Publicado: (2023)

Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy
por: Liu, Yuan-Yuan, et al.
Publicado: (2022)

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial
por: Lim, Myong Cheol, et al.
Publicado: (2022)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
por: Tuninetti, Valentina, et al.
Publicado: (2020)

Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
por: Hollis, Robert L., et al.
Publicado: (2022)

Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion
por: Mahdi, Haider, et al.
Publicado: (2015)

Genetic Analysis and Combined Therapy of Surgery and Chemotherapy for the Progression-Free Survival of a Patient with Ovarian Carcinosarcoma: A Case Report and Literature Review
por: Guo, Shanshan, et al.
Publicado: (2022)

The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis
por: Ding, Ting, et al.
Publicado: (2021)

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab
por: Sostelly, Alexandre, et al.
Publicado: (2019)

Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses
por: Souadka, Amine, et al.
Publicado: (2022)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
por: Dhiman, Pravesh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0it5vlb1kkiltme0qjm3kgsogf